

Luca Piccoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2914944/publications.pdf>

Version: 2024-02-01

22
papers

7,030
citations

471371

17
h-index

713332

21
g-index

30
all docs

30
docs citations

30
times ranked

11409
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. PLoS ONE, 2022, 17, e0263328. | 1.1 | 21 |
| 2 | Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 2022, 602, 664-670. | 13.7 | 917 |
| 3 | Structural basis of malaria RIFIN binding by LILRB1-containing antibodies. Nature, 2021, 592, 639-643. | 13.7 | 8 |
| 4 | Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 2021, 184, 1171-1187.e20. | 13.5 | 541 |
| 5 | Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature, 2021, 593, 136-141. | 13.7 | 648 |
| 6 | Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Reports, 2021, 35, 109292. | 2.9 | 375 |
| 7 | Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity. Nature Communications, 2021, 12, 3532. | 5.8 | 23 |
| 8 | SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science, 2021, 373, 648-654. | 6.0 | 385 |
| 9 | Structural basis of LAIR1 targeting by polymorphic Plasmodium RIFINs. Nature Communications, 2021, 12, 4226. | 5.8 | 1 |
| 10 | SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature, 2021, 597, 97-102. | 13.7 | 385 |
| 11 | SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature, 2021, 599, 114-119. | 13.7 | 1,041 |
| 12 | Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science, 2021, 373, 1109-1116. | 6.0 | 262 |
| 13 | Exceptionally potent human monoclonal antibodies are effective for prophylaxis and treatment of tetanus in mice. Journal of Clinical Investigation, 2021, 131, . | 3.9 | 8 |
| 14 | Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell, 2020, 183, 1024-1042.e21. | 13.5 | 1,195 |
| 15 | European Immunogenicity Platform 11th Open Scientific Symposium on immunogenicity of biopharmaceuticals. Bioanalysis, 2020, 12, 1043-1048. | 0.6 | 1 |
| 16 | A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients. Nature Medicine, 2019, 25, 1402-1407. | 15.2 | 50 |
| 17 | Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 2019, 326, 19-27. | 1.1 | 22 |
| 18 | A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nature Medicine, 2018, 24, 401-407. | 15.2 | 183 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. Multiple Sclerosis Journal, 2018, 24, 1224-1233. | 1.4 | 86 |
| 20 | Public antibodies to malaria antigens generated by two LAIR1 insertion modalities. Nature, 2017, 548, 597-601. | 13.7 | 91 |
| 21 | A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens. Nature, 2016, 529, 105-109. | 13.7 | 140 |
| 22 | Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 0, , . | 13.7 | 101 |